Significance of hemoglobin and hematocrit changes in predicting patient survival and efficacy of neoadjuvant chemotherapy for advanced gastric cancer

Table 4 Comparison of 3-year survival of patients with different hemoglobin and hematocrit levels

Group	Number of cases (n)	1 year	2 years	3 years
Hematocrit (%)
< 33%	75	56 (74.67)	37 (49.33)	22 (29.33)
≥ 33%	110	102 (92.73)	87 (79.09)	69 (62.73)
χ² value		4.997	8.231	5.785
P value		0.040	0.009	0.033
Hemoglobin (g/L)
< 107	102	82 (80.39)	60 (58.82)	40 (39.22)
≥ 107	83	76 (91.57)	64 (77.11)	51 (61.45)
χ² value		8.531	6.389	5.421
P value		0.006	0.027	0.036